Globus Medical, Inc. (NYSE:GMED) Stock Has Average Price Target of $99.46

Key Points

• Analysts maintain a “Moderate Buy” consensus on Globus Medical, with nine buy ratings, three strong-buy ratings and five holds. The average 12-month price target is $99.46, compared with the stock’s reported price of $81.47.
• Globus Medical exceeded quarterly expectations, reporting $1.34 in EPS versus the $1.10 consensus and $789.61 million in revenue. Revenue increased 5.9% year over year, while full-year EPS guidance is $4.95–$5.05.
• Insiders recently sold shares, including directors Stephen Zarrilli and James Tobin, while institutional investors and hedge funds own 95.16% of the stock; insiders hold 18.38%.

Shares of Globus Medical, Inc. (NYSE:GMED - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen ratings firms that are currently covering the company, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating, nine have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $99.46.

A number of equities research analysts have commented on GMED shares. UBS Group assumed coverage on Globus Medical in a research note on Tuesday, July 28th. They issued a "neutral" rating and a $82.00 price target for the company. Truist Financial dropped their price target on Globus Medical from $115.00 to $100.00 and set a "buy" rating on the stock in a research note on Thursday, July 16th. BMO Capital Markets initiated coverage on Globus Medical in a research note on Wednesday, July 8th. They set an "outperform" rating and a $94.00 price target on the stock. BTIG Research restated a "neutral" rating on shares of Globus Medical in a report on Friday, September 18th. Finally, Stifel Nicolaus decreased their price objective on shares of Globus Medical from $95.00 to $80.00 and set a "hold" rating for the company in a research report on Wednesday, July 8th.

Globus Medical Trading Down 0.2%

Shares of GMED stock opened at $81.47 on Friday. Globus Medical has a 12-month low of $59.51 and a 12-month high of $101.40. The business's fifty day simple moving average is $78.03 and its 200-day simple moving average is $81.19. The company has a market cap of $10.94 billion, a PE ratio of 20.84, a PEG ratio of 1.32 and a beta of 0.96.

Globus Medical (NYSE:GMED - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, topping analysts' consensus estimates of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The firm had revenue of $789.61 million during the quarter, compared to analysts' expectations of $782.88 million. During the same quarter last year, the firm earned $0.86 EPS. The business's quarterly revenue was up 5.9% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities analysts forecast that Globus Medical will post 4.99 earnings per share for the current year.

Insider Activity at Globus Medical

In other Globus Medical news, Director Stephen T. Zarrilli sold 25,000 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director owned 25,000 shares in the company, valued at approximately $2,176,000. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director James Tobin sold 30,000 shares of the firm's stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the transaction, the director directly owned 15,000 shares of the company's stock, valued at approximately $1,118,700. This represents a 66.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 18.38% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Globus Medical

Several hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC boosted its holdings in Globus Medical by 2.3% in the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company's stock worth $570,000 after buying an additional 151 shares during the last quarter. Summitry LLC increased its stake in Globus Medical by 2.6% during the 1st quarter. Summitry LLC now owns 8,205 shares of the medical device company's stock worth $707,000 after buying an additional 211 shares in the last quarter. Central Pacific Bank Trust Division increased its stake in Globus Medical by 7.8% during the 3rd quarter. Central Pacific Bank Trust Division now owns 3,057 shares of the medical device company's stock worth $229,000 after buying an additional 220 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Globus Medical by 0.8% during the second quarter. Arizona State Retirement System now owns 31,077 shares of the medical device company's stock valued at $2,455,000 after acquiring an additional 252 shares during the last quarter. Finally, Angeles Wealth Management LLC raised its holdings in shares of Globus Medical by 5.0% during the second quarter. Angeles Wealth Management LLC now owns 5,894 shares of the medical device company's stock valued at $466,000 after acquiring an additional 280 shares during the last quarter. 95.16% of the stock is owned by institutional investors and hedge funds.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.